ClinicalTrials.gg
Not yet recruitingNCT07856030Updated Oct 2, 2026

Enhancing Patient Wellbeing Through Integration of Social Prescribing, Transitional Care, and Place-based Care in Community Hospitals Settings

An interventional study of SingHealth Community Hospitals Place-based Care in Community Hospital Patients Discharging to the Community, sponsored by SingHealth Community Hospitals. Not yet recruiting at 2 sites in Singapore. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by SingHealth Community Hospitals · Not applicable, Interventional, and Health services research

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The study aims to find out whether placed-based care (PBC), helps patients receive better support when they return home after leaving the community hospital, compared with the usual care provided.

Read the detailed description

This study addresses the critical need for a rigorous evaluation of PBC as an integrated model of care within community hospital settings. By employing a pragmatic parallel cluster randomised controlled trial design, the study will generate robust evidence on the effectiveness of PBC in real-world practice while minimising contamination at the ward level. The cluster-based design is appropriate given that the intervention is delivered at the ward level and cannot be implemented at the individual patient level without risk of spillover effects.

The use of validated outcome measures, including the CTM-15 as the primary outcome, will enable comprehensive assessment of care transition quality alongside broader outcomes related to patient wellbeing and healthcare utilisation. In addition, the study incorporates a mixed-methods approach, guided by the Practical, Robust Implementation and Sustainability Model (PRISM), to provide insights into implementation processes, mechanisms of action, and contextual factors influencing effectiveness (McCreight et al., 2019; Rabin et al., 2022).

Findings from this study will inform policy and service planning decisions regarding the scaling and sustainability of integrated social prescribing models within Singapore's healthcare system and contribute to the international evidence base on complex transitional care interventions.

02

Conditions studied

  • Community Hospital Patients Discharging to the Community

Keywords

  • Community Hospital
  • Social Prescribing
  • Placed Based Care
03

In context

Lead sponsor

SingHealth Community Hospitals is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is (male or female) ≥ 50 years of age at Recruitment.
  • Participant is expected to discharge to the community.
  • Participant is able to converse in either English, Mandarin, or Malay
  • Participant is able to sign the written .
  • Participant is considered reliable and capable of adhering to the protocol.
  • Participant is able to complete all the questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Participant is planned for hospice discharge.
  • Participant is planned for nursing home placement, transitional shelter or care facilities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
720 participants (estimated)

Study arms

  • Active comparator
    SCH Place-based Care Intervention Ward

    SingHealth Community Hospitals Place-based Care model will be utilised in the ward on top of standard of care treatment.

    Other: SingHealth Community Hospitals Place-based Care

  • No intervention
    SCH Control Ward

    Wards will have normal standard of care treatment.

Interventions

  • OtherSingHealth Community Hospitals Place-based Care

    Place-based Care (PBC) at SingHealth Community Hospitals represents a significant evolution of these approaches, addressing the limitations of fragmented care by integrating social prescribing with structured transitional care. Within community hospital settings, PBC encompasses five core domains: coordinated specialist outpatient follow-ups, linkage to community resources, medication adherence support, primary care transition planning, and caregiver education and self-care empowerment. This integrated model shifts the conventional discharge process from a primarily episodic and medically driven approach to a comprehensive, person-centred care pathway that incorporates both clinical and social assessment, coordinated care planning, supported transition, and structured follow-up. By embedding social prescribing within the continuum of care, PBC aims to improve both clinical outcomes and patient experience during vulnerable transition periods.

06

What researchers measure

Primary outcomes

  1. Care Transition Quality (CTM-15)

    The CTM-15 is the primary outcome measure for this study and aligns closely with the five core domains of the PBC intervention: specialist outpatient clinic (SOC) follow-up coordination, community resource linkage, medication adherence support, primary care transition planning, and caregiver and self-care capability. The CTM-15 is a validated 15-item instrument that assesses the quality-of-care transitions from the patient's perspective, capturing key domains such as medication management, understanding of the care plan, preparation for self-care, and coordination across healthcare settings.

    Time frame: T1: 21 Days Post-Discharge

07

Study locations

2 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Nov 17, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856030
Lead sponsor
SingHealth Community Hospitals
Responsible party
Lee Kheng Hock (Associate Professor Lee Kheng Hock, SingHealth Community Hospitals) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 17, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

A/Prof Lee Kheng Hock
Contact
lee.kheng.hock@singhealth.com.sg
69703201
Kheng Hock Lee
principal investigator · SingHealth Community Hospitals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion